Major drug companies and smaller biopharmaceutical companies are expending enormous amounts of effort and capital toward the development of new drugs for diabetes and obesity because of the growing importance of these diseases and the large market for therapies to treat them. During the past five years, several new diabetes drugs and two new obesity drugs have been introduced. Decision Resources, Inc., announces a new report, Next-Generation Metabolic Disease Therapeutics: An Analysis of Eight Therapeutic Pipelines for Diabetes and Obesity that analyzes the opportunities and hurdles awaiting new drugs in the metabolic disease marketplace.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Several drugs-most notably those from a new class of drugs called thiazolidinediones (SmithKline Beecham's Avandia and Eli Lilly/Takeda's Actos) to treat insulin resistance in type 2 diabetes patients, and two new antiobesity drugs (Knoll Pharmaceuticals' Meridia and Roche's Xenical)-are breakthrough products that offer important new options in addressing these often difficult-to-treat diseases. Nevertheless, the pharmaceutical industry and the medical community have a long way to go to address the unmet medical needs in metabolic diseases. The most glaring deficit in treating metabolic diseases is the lack of specific drugs for diabetic complications. Whether emerging drugs now in the pipeline will have a major impact on treatment of these conditions remains to be seen. Current antiobesity drugs have limited efficacy, and current drugs for type 2 diabetes-even in combination therapies- fail to fully normalize blood glucose in a majority of patients.

Next-Generation Metabolic Disease Therapeutics examines the current state of drug discovery and development pipelines in diabetes (including types 1 and 2 diabetes and diabetic complications) and obesity. The development pipelines in metabolic diseases of eight selected biopharmaceutical companies are examined, including deals between these companies and large pharmaceutical companies. The companies profiled are Alteon Pharmaceuticals, Amgen, Amylin Pharmaceuticals, Ligand Pharmaceuticals, Metabolex, Millennium Pharmaceuticals, Trega Biosciences, and Tularik. All have major programs in metabolic diseases, and in some cases, they specialize solely in this disease area.

Next-Generation Metabolic Disease Therapeutics: An Analysis of Eight Therapeutic Pipelines for Diabetes and Obesity is available for $5,000.00. Contact: Cindy Ohlman, 781.296.2521 (telephone), 781.296.2525 (fax), or ohlman@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, Inc., 781-296-2521,
ohlman@dresources.com

Decision Resources Evaluates Investigational Agents to Treat Alzheimer's Disease, Parkinson's Disease, and Other Neurodegenerative Diseases

View Now